|
| FDA advisory committee recommends approval of Cinryze for hereditary angioedema |
6 May 08, 08:43 |
|
| Lev Pharmaceuticals, Inc. said the Blood Products Advisory Committee to the US Food and Drug Administration (FDA) voted unanimously that there is sufficient evidence of the safety and efficacy for the approval of Cinryze (C1 inhibitor) for the prophylactic treatment of hereditary angioedema (HAE), also known as C1 inhibitor deficiency. |
| more |
|
